Naunyn-Schmiedeberg's Archives of Pharmacology
Cure8 research brief
Why This Matters
This study suggests the cancer drug lapatinib reduced colon damage and liver changes in a rat model of chemical colitis, which could point to new research directions for IBD treatments or gut–liver injury mechanisms.
Who Should Pay Attention
Researchers and clinicians studying IBD pathophysiology, drug-repurposing or gut–liver interactions; patients interested in IBD research updates (not for treatment guidance).
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthMetadata only
What To Know
This paper reports an animal (rat) study testing the anti-cancer drug lapatinib in an acetic acid–induced model of ulcerative colitis and associated liver injury. The authors present mechanistic discussion linking effects to inflammatory and oxidative-stress pathways.
The findings are preclinical: the experiment used chemically induced colitis in rats rather than human patients, so results do not directly translate into clinical benefit for people with UC or Crohn’s disease.
Lapatinib is not an approved IBD therapy; this work suggests possible drug-repurposing hypotheses that would require further study, including safety evaluation in relevant clinical settings. If you are reading because of personal IBD care, this is early-stage research and not a basis for changing treatment.
Clinicians and researchers interested in drug-repurposing, tyrosine kinase inhibitors, or gut–liver axis mechanisms may find the methodology and pathway analyses most relevant.
Keep In Mind
Preclinical animal-model results are hypothesis-generating only. Lapatinib is an oncology drug with its own safety profile; human trials would be needed before any clinical use in IBD. The article is a full-text experimental study in an academic journal (Naunyn-Schmiedeberg’s Archives of Pharmacology).
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationNaunyn-Schmiedeberg's Archives of Pharmacology
PublisherSpringer Science and Business Media LLC
AuthorsAbdullah S. Al-Resheedi, Hoda E. Kafl, Ghada M. Suddek
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedJul 16, 2026, 12:00 AM
Content availableMetadata only
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Dendrobium huoshanense polysaccharides alleviate DSS-induced ulcerative colitis in mice: comparison between different parts of plant and role of GLP-1/GLP-1R axis.
This study identifies a plant-derived polysaccharide (from the stem of Dendrobium huoshanense) that reduced inflammation and tissue injury in a mouse model of ulcerative colitis and points to GLP-1 signaling as a likely...
Gegen Qinlian Decoction Mitigates DSS-Induced Acute Colitis and Reinstates Gut Barrier Function in Mice, Correlating with Suppressed IL-33/ST2 Signaling.
Researchers used a standard mouse colitis model to show a traditional herbal formula reduced inflammation and improved gut barrier markers, implicating the IL-33/ST2 immune pathway. This could guide future preclinical...
Protective effects of Brassica rapa L. water extract against DSS-induced acute UC-like colitis in mice and its regulatory mechanisms involving gut microbiota and the intestinal mucosal barrier
The study identifies a plant extract that reduced colitis-like injury in mice and altered gut microbes and intestinal barrier markers, which could inform future preclinical work. For people with IBD, this is early-stage...